Navigation Links
PLUS Diagnostics First National Laboratory to Offer Highly Specialized Gastrointestinal Tests
Date:6/1/2009

Company Expands Diagnostic Services with K9 Clone DOG-1 Immunohistochemical and H. pylori Monoclonal Antibody Tests

LAKEWOOD, N.J., June 1 /PRNewswire/ -- PLUS Diagnostics, a leading U.S. anatomic pathology company offering a full range of multi-specialty services, announced today that it is the first national laboratory to offer a highly specialized test that definitively diagnoses the rare gastrointestinal stromal tumor ("GIST"). Known as the K9 clone DOG-1 immunohistochemical assay, the new test is expected to identify up to 15 percent more people who suffer from the tumor than current tests.

PLUS Diagnostics also announced that it is the first U.S. laboratory to beta test an H. pylori monoclonal antibody test that detects H. pylori infection. Afflicting as many as 30 percent of Americans, H. pylori can be difficult to distinguish from other bacteria in routine staining assays. The infection, which is commonly caused by ingesting contaminated water or food, can cause peptic ulcer disease and gastric malignancy when left untreated. PLUS Diagnostics' new test is expected to reduce the number of false positive H. pylori cases.

"These tests are at the forefront of science and innovation, and support our goal of providing our customers with leading diagnostic services that enable them to offer their patients the highest quality of care," said Doug Berg, chief executive officer, PLUS Diagnostics. "We will continue to identify and invest in the newest tests and technologies that are uniquely tailored to supporting doctors and specialists with diagnosing a range of cancers and disorders."

Dr. Ali Riba, associate medical director for PLUS Diagnostics, added: "It is exciting to be part of a laboratory that is significantly investing in gastrointestinal services. We have the potential to help doctors save lives by definitively diagnosing the rare GIST tumor when traditional tests are not able to do so. Similarly, our beta test for H. pylori is expected to improve the accuracy of today's immunohistochemical tests, so doctors can immediately determine whether their patients require treatment."

PLUS Diagnostics has expanded its services since the company partnered with Water Street Healthcare Partners, a leading private equity firm focused exclusively on health care. It recently opened a West Coast laboratory and announced plans to expand into diagnostics services for hematology/oncology, in addition to the gastroenterology and urology specialties it serves today.

About PLUS Diagnostics

PLUS Diagnostics is a leading national anatomic pathology company that provides a full range of multi-specialty services, including extensive diagnostic procedures and specialist consultations. Accredited by the College of American Pathologists, PLUS Diagnostics has long been recognized for exceptional service and quality. The company currently focuses on a broad base of specialty pathology services, including urology and gastroenterology with plans to expand into hematopathology this year. For more information, visit, www.plusdx.com.


'/>"/>
SOURCE PLUS Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer
2. Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
3. Quest Diagnostics to Speak at the Deutsche Bank 34th Annual Healthcare Conference
4. Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online
5. Quest Diagnostics Declares Quarterly Cash Dividend
6. Beckman Coulter Pending Acquisition of Olympus Diagnostics Systems Passes Milestone with U.S. Regulatory Approval
7. Quest Diagnostics Announces Annual Shareholders Meeting Webcast
8. Quest Diagnostics to Speak at the Bank of America and Merrill Lynch 2009 Healthcare Conference
9. Cocaine Use Among U.S. Workers Declines Sharply in 2008, According to Quest Diagnostics Drug Testing Index(TM)
10. Personalized Medicine Makes Significant Headway Following the Rapid Evolution of U.S. Molecular Diagnostics Market, Finds Frost & Sullivan
11. Instrumentation Laboratory Wins Patent Infringement and Unfair Competition Trial Against Diagnostica Stago Relating to Reagents for Hemostasis Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, ... St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was ... address the conference about her unique specialization in treating Lipedema. Dr. Byrd is considered ...
(Date:5/5/2016)... ... , ... Is the part in your hair widening? Are you finding more ... a good opportunity to raise awareness about a common condition among women: hair loss. ... women experience hair loss or ‘thinning’ by the time they reach menopause, but many ...
(Date:5/4/2016)... ... 04, 2016 , ... ProList is a set of 30 self-animating bullet points ... editors can easily create lists for presentations, youtube productions, and more. Simply choose ... is the perfect complement to presentation style videos. , ProList is a package of ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... and interview techniques, seeks to add a deeper understanding of the program, policy ... weaknesses, and each answers different yet important questions. , In a new brief ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Business Conference. The conference opened on Tuesday with Frank Luntz, sharing a dynamic, ... PDMP Solution provided a deep dive on NCPDP’s model solution to help stem ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... York , May 4, 2016 ... Transparency Market Research entitled "Brain Computer Interface Market - Global ... - 2024," the  global brain computer interface (BCI) market  is ... 2024. The market is estimated to expand at a ... 2016 to 2024. A BCI device provides ...
(Date:5/4/2016)... NESS ZIONA, Israel , May ... BVXV, TASE: BVXV) announced today that BiondVax,s CEO, Dr. ... 2016 conference in New York City . ... presenting at 10:30am at Pioneers 2016, a conference presented by ... New York Palace Hotel. The BiondVax presentation that ...
(Date:5/4/2016)... -- Yissum Research Development Company of ... it had signed an exclusive world-wide licensing and research ... protein degradation and immunomodulatory drugs for cancer and immune ... representing first-in-class therapy for hematologic and solid malignancies. Financial ... The novel technology was developed by Yinon Ben-Neriah ...
Breaking Medicine Technology: